ArticleFungal biology and biotechnology2026
Antifungal resistance landscapes in major fungal pathogens in Zhejiang, China.
Article in Fungal biology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundInvasive fungal infections caused by Aspergillus fumigatus and other pathogenic fungi represent a major global health threat, with treatment increasingly complicated by the emergence of antifungal drug resistance. Azole antifungals serve as the first-line therapy for aspergillosis, but resistance rates vary substantially across geographical regions. This study aimed to characterize the antifungal resistance landscape among clinical fungal isolates from Hangzhou and Yiwu cities in Zhejiang Province, Eastern China, and to elucidate the molecular mechanisms underlying azole resistance in Aspergillus fumigatus.
resultsWe analyzed 110 Aspergillus clinical isolates for antifungal susceptibility. Among A. fumigatus strains, 8.6% exhibited azole resistance, with half of these harboring the tandem repeat mutation TR34/L98H in the cyp51A gene. One resistant strain carried the TR46/Y121F/T289A mutation combination. Minimum inhibitory concentration testing revealed that 8.6% of A. fumigatus isolates were resistant to amphotericin B We identified one resistant isolate without known resistance mutations and characterized it through whole-genome sequencing and transcriptomic analysis. Novel mutations S437F in cyp51A and P298T in hmg1 were discovered; however, functional validation using CRISPR-Cas9 demonstrated these mutations do not directly confer resistance. Instead, transcriptomic profiling revealed significant upregulation of ergosterol biosynthesis pathway genes and efflux transporter genes, suggesting alternative resistance mechanisms. Among non-A. fumigatus species, all A. niger isolates displayed resistance to itraconazole and posaconazole.
conclusionsThis comprehensive regional surveillance reveals concerning patterns of antifungal resistance among major human pathogenic fungi in Zhejiang Province, China. The identification of both classical resistance mutations and novel transcription-mediated resistance mechanisms highlights the complex and evolving nature of antifungal resistance. These findings emphasize the critical need for continued surveillance programs and rapid resistance detection methods to inform clinical treatment strategies and improve patient outcomes.
Indexed as
Identifiers
42919349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.